ABBV
AbbVie Inc. · Healthcare · Drug Manufacturers - General
All ownership figures: tracked 13F managers only, common-stock positions, reporting period Q2 2024
| Quarter | Holders | Δ | Shares | Reported value | New | Exits |
|---|---|---|---|---|---|---|
| Q2 2026 | 183 | +6 | 1.07B | $270.09B | +9 | −2 |
| Q1 2026 | 179 | -3 | 1.05B | $227.15B | +2 | −6 |
| Q4 2025 | 181 | -3 | 1.14B | $259.75B | +1 | −3 |
| Q3 2025 | 27 | 0 | 673.15M | $155.83B | — | −1 |
| Q2 2025 | 25 | +2 | 519.81M | $96.45B | +2 | — |
| Q1 2025 | 20 | 0 | 175.76M | $36.80B | — | — |
| Q4 2024 | 20 | 0 | 178.61M | $31.72B | — | — |
| Q3 2024 | 19 | 0 | 95.00M | $18.73B | +1 | −1 |
| Q2 2024 | 19 | — | 90.79M | $15.55B | — | — |
| # | Manager | Shares | Δ shares | Value | Their weight | Held | ||
|---|---|---|---|---|---|---|---|---|
| 1 | Geode Capital Management ✦ (passive) | 36.68M | — | $6.28B | 0.6% | n/c | 1 | SEC ↗ |
| 2 | Geode Capital Management ✦ (passive) | 36.68M | — | $6.28B | 0.6% | n/c | 1 | SEC ↗ |
| 3 | Norges Bank ✦ (passive) | 22.48M | — | $3.86B | 0.6% | n/c | 1 | SEC ↗ |
| 4 | T. Rowe Price ✦ | 10.94M | — | $1.88B | 0.2% | n/c | 1 | SEC ↗ |
| 5 | T. Rowe Price ✦ | 10.94M | — | $1.88B | 0.2% | n/c | 1 | SEC ↗ |
| 6 | Capital World Investors ✦ | 10.28M | — | $1.76B | 0.3% | n/c | 1 | SEC ↗ |
| 7 | Wellington Management ✦ | 2.88M | — | $494.42M | 0.1% | n/c | 1 | SEC ↗ |
| 8 | Wellington Management ✦ | 2.88M | — | $494.42M | 0.1% | n/c | 1 | SEC ↗ |
| 9 | Wellington Management ✦ | 2.88M | — | $494.42M | 0.1% | n/c | 1 | SEC ↗ |
| 10 | Wellington Management ✦ | 2.88M | — | $494.42M | 0.1% | n/c | 1 | SEC ↗ |
| 11 | Wellington Management ✦ | 2.88M | — | $494.42M | 0.1% | n/c | 1 | SEC ↗ |
| 12 | Wellington Management ✦ | 2.88M | — | $494.42M | 0.1% | n/c | 1 | SEC ↗ |
| 13 | Wellington Management ✦ | 2.88M | — | $494.42M | 0.1% | n/c | 1 | SEC ↗ |
| 14 | Adage Capital Partners ✦ | 1.42M | — | $243.61M | 0.5% | n/c | 1 | SEC ↗ |
| 15 | AQR Capital Management ✦ | 1.40M | — | $237.81M | 0.4% | n/c | 1 | SEC ↗ |
| 16 | AQR Capital Management ✦ | 1.40M | — | $237.81M | 0.4% | n/c | 1 | SEC ↗ |
| 17 | AQR Capital Management ✦ | 1.40M | — | $237.81M | 0.4% | n/c | 1 | SEC ↗ |
| 18 | Renaissance Technologies ✦ | 1.30M | — | $223.78M | 0.4% | n/c | 1 | SEC ↗ |
| 19 | Millennium Management ✦ | 980.23K | — | $168.13M | 0.1% | n/c | 1 | SEC ↗ |
| 20 | D. E. Shaw & Co. ✦ | 918.63K | — | $157.56M | 0.2% | n/c | 1 | SEC ↗ |
| 21 | D. E. Shaw & Co. ✦ | 918.63K | — | $157.56M | 0.2% | n/c | 1 | SEC ↗ |
| 22 | Marshall Wace ✦ | 885.91K | — | $151.95M | 0.2% | n/c | 1 | SEC ↗ |
| 23 | Bridgewater Associates ✦ | 288.52K | — | $49.49M | 0.3% | n/c | 1 | SEC ↗ |
| 24 | Arrowstreet Capital ✦ | 183.07K | — | $31.40M | 0.0% | n/c | 1 | SEC ↗ |
| 25 | Gotham Asset Management ✦ | 46.08K | — | $7.90M | 0.1% | n/c | 1 | SEC ↗ |
| 26 | Fisher Asset Management ✦ | 39.80K | — | $6.83M | 0.0% | n/c | 1 | SEC ↗ |
| 27 | Two Sigma Investments ✦ | 17.07K | — | $2.93M | 0.0% | n/c | 1 | SEC ↗ |
| 28 | GAMCO Investors ✦ | 14.75K | — | $2.53M | 0.0% | n/c | 1 | SEC ↗ |
| 29 | Dodge & Cox ✦ | 11.01K | — | $1.89M | 0.0% | n/c | 1 | SEC ↗ |
| 30 | Harris Associates (Oakmark) ✦ | 1.49K | — | $256,079 | 0.0% | n/c | 1 | SEC ↗ |
“Their weight” = the position's share of that manager's reported 13F equity value — the conviction measure. ✦ = curated manager.
New buyers
| No new tracked buyers this quarter. |
Exited
| No tracked exits this quarter. |
Full-market context: across ALL 13F filers (SEC structured data, Q1 2026): 1 holders, 82.20K shares, $17,877 reported. This is a different, older period than the tracked-universe figures above and the two are never mixed.
What else this security's tracked holders most often hold — shared-ownership counts, not fundamental relationships.
Open-market purchases (P)
No open-market insider purchases in our coverage window.
Open-market sales (S)
Officer · 32.71K sh · $8.18M
Awards, exercises and tax withholding are never counted as buys or sales here. Methodology